Among patients with PsA, MetS is associated with certain degenerative changes in the spine and entheses but not with peripheral or axial radiographic damage.

Psoriatic arthritis represents a complex interplay between two distinct conditions. For most people, the skin symptoms appear first—typically red, scaly patches known as plaques that can appear ...

Adam also apologised to his followers for having not been "very vocal" about his experience with arthritis lately. He told them in the recent post on Instagram: "[I'm] just struggling and trying ...

Most of the time, psoriasis is the first symptom of psoriatic arthritis. It causes silvery-white skin lesions called plaques, which may appear on your scalp, elbows, knees, and lower back. Eventually, ...

effective home remedy that can help ease arthritis symptoms. Acharya Balkrishna advises taking equal parts of ajwain, saunth, and harad and grinding them together into a fine powder. This herbal ...

Johnson & Johnson announced that the Tremfya (guselkumab) phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing ...

For approximately 85% of patients diagnosed with psoriatic arthritis, the skin manifestations of psoriasis emerge first, with joint symptoms typically developing 7-10 years after initial skin ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis. Findings from the Phase ...

Patients with psoriatic arthritis (PsA) experienced longer diagnostic delays than matched patients with rheumatoid arthritis (RA). Patients with polyarticular PsA received less intensive disease ...

Psoriatic arthritis (PsA) is a chronic (long-lasting) condition that combines the skin-related symptoms of psoriasis with the joint-related symptoms of arthritis. PsA is an autoimmune disease ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...